共 231 条
[1]
Bilimoria K(2007)Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database Cancer 110 738-744
[2]
Bentrem D(2008)Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer J Clin Oncol 26 1178-1179
[3]
Ko C(2009)Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer Oncology 76 270-274
[4]
Ritchey J(1997)Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403-2413
[5]
Stewart A(2005)Phase III randomized comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer Eur J Cancer 3 3-485
[6]
Winchester D(2006)Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study Br J Cancer 94 481-vi127
[7]
Talamonti M(2007)Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice Ann Oncol 18 vi124-600
[8]
Boeck S(1996)Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer Ann Oncol 7 593-339
[9]
Heinemann V(2008)Short time to progression under first-line chemotherapy is a negative prognostic factor for time to progression and residual survival under second-line chemotherapy in advanced pancreatic cancer Oncology 73 335-90
[10]
Brell J(2008)Optimal second line treatment options for gemcitabine refractory advanced pancreatic cancer patients. Can we establish standard of care with available data? JOP 9 83-495